Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Advanced Salivary Gland Carcinoma
NCT03146650Phase 2Active, not recruiting
- Sponsor
- Northwestern University
- Start
- May 2017
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in adenoid cystic carcinoma (ACC) and salivary gland carcinoma (SGC), sponsored by Northwestern University. Primary endpoints: Progression-Free Survival up to 2 years and Median Progression-free Survival up to 2 years. Started May 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
adenoid cystic carcinoma (ACC)salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT03146650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146650.